(CIBER-BBN) was officially established in 2006, with its head office in Zaragoza. The CIBER-BBN, consortium created under the leadership of the Carlos III Health Institute (ISCIII) of the Spanish Ministries of Economy and Health, to promote research excellence and build a critical mass of researchers in the field of Biomedicine and Health Sciences, is a multidisciplinary and multi-institutional translational research center integrating basic, clinical and technological research. As of January 1st, 2014 the CIBER-BBN merged with other seven existing CIBERs in Spain in a single management unit with headquarters in Madrid, which involves more than 5.000 Spanish researchers in biomedicine. The organizational structure of CIBER is based on the research groups that compose it and which have been selected on a basis of scientific excellence in the three areas of research of the cluster.
Currently, its center of Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN (www.ciber-bbn.es/en), employs 130 researchers directly hired by the CIBER and conduct their research at any of the 46 participating groups, as well as more than 350 associate researchers, who although having a contract with the corresponding consortium institution they are considered as attached-to-CIBER staff.
“To become a centre of reference in research and innovation both at a national and international level achieving a leading position in technological advances and their transfer to clinical practice.”
“To perform a research of excellence aimed at industrial transfer and clinical translation through the development of the scientific areas of bioengineering, biomaterials and nanomedicine.”
The CIBER- BBN Research Program is organized in three different scientific areas and eight strategic lines. The area of Bioengineering consists of the strategic lines of Multimodal Diagnosis and Intelligent Devices, the area of Biomaterials of the lines of Cell and Gen Therapy, Tissue Engineering and Prostheses and Implants, while the area of Nanomedicine includes the strategic lines of Nanodiagnoses, Therapeutic Nanosystmes and Nanobiotechnology.
CIBER -BBN research groups are continuously evaluated under the light of scientific excellence by using markers such as their number of publications (632, only during 2013; 426 in the 1st quartile), but also for their activities in obtaining financing in competitive calls, the transfer of technology and their relations with the private sector. During its rather short life, CIBER-BBN was awarded over 100 grants and raised over € 170 millions in competitive calls (HEALTH, NMP, PEOPLE, ERA- NET EuroNanoMed and ERC Starting and Advanced Grants) and in the contracts with companies, having signed more 200 contracts and supporting more than 65 patents in 2013.